Ligand Pharmaceuticals (LGND) Return on Sales (2010 - 2026)

Ligand Pharmaceuticals' Return on Sales history runs 16 years deep, the most recent figure standing at 0.0% for Q1 2026.

• In Q1 2026, Return on Sales rose 1.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.01% (up 1.0% YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
• Return on Sales came in at 0.0% for Q1 2026 at Ligand Pharmaceuticals, down from 0.01% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.01% in Q3 2025 to a low of 0.01% in Q1 2025.
• A 5-year average of 0.0% and a median of 0.0% in 2022 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales retreated 1 bps in 2024 and increased 1 bps in 2025, its largest moves.
• Ligand Pharmaceuticals' Return on Sales stood at 0.0% in 2022, then jumped by 78 bps to 0.0% in 2023, then tumbled by 5627 bps to 0.01% in 2024, then surged by 203 bps to 0.01% in 2025, then plunged by 134 bps to 0.0% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.01%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison